Diversigen, Inc., has been selected by the Crohn’s & Colitis Foundation as a preferred provider for metagenomics and microbiome analysis services and to serve as a central lab for the generation of high quality microbiome data to be incorporated into the IBD Plexus® platform. The Crohn’s & Colitis Foundation is the largest non-profit, voluntary, health organization dedicated to finding cures for inflammatory bowel diseases (IBD).

IBD Plexus is a first-of-its-kind research information exchange platform designed to centralize data and bio samples from diverse research initiatives to advance science, accelerate precision medicine, and transform the care of IBD patients. This partnership will allow academic and industry researchers to take advantage of Diversigen high quality CLIA/CAP microbiome analytical capabilities, ensuring that the same protocols and analytical pipelines are used – a crucial component to create uniform and reproducible datasets.